Overall survival [clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45]

Overall survival [clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45]

Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission [clinicaltrials:NCT00454168]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Overall survival [clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45]

Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45
Bio2RDF identifier
0000d6976b16ff864d4a4a05aa483f45
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45
measure [clinicaltrials_vocabulary:measure]
description
Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
identifier
clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45
title
Overall survival
@en
inDataset
type
label
Overall survival [clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45]
@en